Vice President, Development
Angeline Shashlo’s 30-year career, which spans both the pharmaceutical and biotechnology industries, has focused on the development and registration of pharmaceuticals, biologicals and devices. She has worked extensively with the FDA and EU regulatory authorities, leading initiatives to obtain and maintain product registration in a wide range of therapeutic areas including metabolic diseases and diabetes. She has broad experience in product development and management, manufacturing, foreign and domestic regulatory affairs and quality assurance, with numerous Investigational New Drugs (IND), Investigational Medicinal Product Dossiers (IMPD), Canadian and foreign clinical trial applications, New Drug Applications (NDA), Marketing Authorization Applications (MAA), and international registration dossiers and product launches to her credit. She was instrumental in obtaining the industry’s first export exemption to Japan and represented the pharmaceutical industry in negotiations with the U.S. Department of Commerce and the U.S. Department of Defense to secure revision of the legislation regarding the export of technical information.
Previously, Ms. Shashlo served as vice president of development for MSDC. Prior to that, Ms. Shashlo served as senior vice president of regulatory affairs, quality assurance and project management at Tobira Therapeutics, Inc., a company she co-founded. Previously, Ms. Shashlo was vice president of regulatory affairs and project management at Incyte Corporation, senior vice president at Genaera Corporation and director of regulatory affairs at Ligand Pharmaceuticals. She also has held positions at Wyeth and The Upjohn Company. She began her career as a staff pharmacist at Harper Grace Hospitals in Detroit before joining The Upjohn Company in 1982.
Ms. Shashlo received a B.S. in pharmaceutical sciences from the University of Michigan and is a registered pharmacist in the state of Michigan.